Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Century Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

11/22/2021 | 08:01am EST

PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participated in a fireside chat in advance of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 30- December 2, 2021.

A recording of the fireside chat will be available today at 10:00 AM ET on the Events & Presentations section of Century’s website and will be available for 30 days.

About Century Therapeutics

Century Therapeutics, Inc. (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit www.centurytx.com.

Century Therapeutics Forward-Looking Statement

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:
Company: Elizabeth Krutoholow – investor.relations@centurytx.com
Investors: Melissa Forst/Maghan Meyers – century@argotpartners.com
Media: Joshua R. Mansbach – century@argotpartners.com


Primary Logo

Source: Century Therapeutics, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about CENTURY THERAPEUTICS, INC.
01/13CENTURY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/11CENTURY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
01/10CENTURY THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
01/04Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021CENTURY THERAPEUTICS, INC.(NASDAQGS : IPSC) added to S&P Global BMI Index
CI
2021CENTURY THERAPEUTICS, INC.(NASDAQGS : IPSC) added to NASDAQ Biotechnology Index
CI
2021Century Therapeutics to Join Nasdaq Biotechnology Index
MT
2021Century Therapeutics Added to the NASDAQ Biotechnology Index
GL
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -93,3 M - -
Net cash 2021 343 M - -
P/E ratio 2021 -4,11x
Yield 2021 -
Capitalization 747 M 747 M -
EV / Sales 2021 -
EV / Sales 2022 34,8x
Nbr of Employees -
Free-Float -
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 13,20 $
Average target price 36,00 $
Spread / Average Target 173%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Cynthia M. Butitta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.-16.77%747
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508